{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-22-000049","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2022-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.664615+00:00","generated_at":"2026-06-22T23:58:04.437500+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Travere Q3 net loss $69.7M; PDUFA for sparsentan extended to Feb 17, 2023; EMA accepts CMA","bullets":["Net loss $69.7M ($1.09/share) vs $35.6M ($0.59) YoY; adjusted net loss $48.9M ($0.76).","Net product sales $50.8M, down from $54.2M; total revenue $53.5M.","FDA set new PDUFA date Feb 17, 2023 for sparsentan in IgAN after REMS update.","EMA accepted CMA application for sparsentan in IgAN; decision expected H2 2023.","Cash, equivalents & marketable securities $506.3M; DUPLEX FSGS data expected H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-22-000049","json":"https://secwatch.observer/filing/0001438533-22-000049.json","markdown":"https://secwatch.observer/filing/0001438533-22-000049.md","text":"https://secwatch.observer/filing/0001438533-22-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853322000049/0001438533-22-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853322000049/tvtx-20221027.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T23:58:04.437500+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e7ed7e5bb74d04da5fe97bcf1640b500322db9a9","claim":"Travere Therapeutics, Inc. reported financial results for the quarter ended September 30, 2022.","evidence_excerpt":"On October 27, 2022, Travere Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853322000049/0001438533-22-000049-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}